A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB<sub>2</sub> receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB<sub>2</sub>, and A-796,260 was found to be a highly selective CB<sub>2</sub> agonist with little affinity for CB<sub>1</sub>, having a CB<sub>2</sub> K<sub>i</sub> of 4.6 nM vs 945 nM at CB<sub>1</sub>. It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.
As of October 2015 A-796,260 is a controlled substance in China.